Company registration number 01649470 (England and Wales)
THERAPOSTURE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
THERAPOSTURE LIMITED
CONTENTS
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 5
THERAPOSTURE LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
135,934
184,358
Current assets
Stocks
633,058
904,536
Debtors
314,829
343,435
Cash at bank and in hand
26,522
3,786
974,409
1,251,757
Creditors: amounts falling due within one year
(657,352)
(909,802)
Net current assets
317,057
341,955
Total assets less current liabilities
452,991
526,313
Creditors: amounts falling due after more than one year
(56,891)
(142,189)
Provisions for liabilities
(33,058)
(45,194)
Net assets
363,042
338,930
Capital and reserves
Called up share capital
10,060
10,060
Profit and loss reserves
352,982
328,870
Total equity
363,042
338,930
THERAPOSTURE LIMITED
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
31 DECEMBER 2024
31 December 2024
- 2 -

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 16 September 2025 and are signed on its behalf by:
Mr D J Holtum
Director
Company registration number 01649470 (England and Wales)
THERAPOSTURE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information

Theraposture Limited is a private company limited by shares incorporated in England and Wales. The registered office is Kingdom Avenue, Northacre Industrial Park, Westbury, Wiltshire, BA13 4WE.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Over the 15 year period of the lease
Fixtures and fittings
15% straight line
Computers
33% straight line
Motor vehicles
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

THERAPOSTURE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the statement of financial position as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

THERAPOSTURE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
31
35
3
Tangible fixed assets
Total
£
Cost
At 1 January 2024
804,303
Additions
37,520
Disposals
(108,927)
At 31 December 2024
732,896
Depreciation and impairment
At 1 January 2024
619,945
Depreciation charged in the year
73,163
Eliminated in respect of disposals
(96,146)
At 31 December 2024
596,962
Carrying amount
At 31 December 2024
135,934
At 31 December 2023
184,358

Hire Purchase liabilities of £44,057 (2023: £125,776) are secured against the assets to which they relate.

4
Parent company

The company is a 100% owned subsidiary of R.K.J. Holdings Limited, a company incorporated in England and Wales.

2024-12-312024-01-01falsefalsefalse16 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr L S BraddellMrs A C BraddellMr D J HoltumMrs B A HoltumMrs B A Holtum016494702024-01-012024-12-31016494702024-12-31016494702023-12-3101649470core:ShareCapital2024-12-3101649470core:ShareCapital2023-12-3101649470core:RetainedEarningsAccumulatedLosses2024-12-3101649470core:RetainedEarningsAccumulatedLosses2023-12-3101649470bus:Director32024-01-012024-12-3101649470core:LandBuildingscore:LongLeaseholdAssets2024-01-012024-12-3101649470core:FurnitureFittings2024-01-012024-12-3101649470core:ComputerEquipment2024-01-012024-12-3101649470core:MotorVehicles2024-01-012024-12-31016494702023-01-012023-12-31016494702023-12-3101649470bus:PrivateLimitedCompanyLtd2024-01-012024-12-3101649470bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3101649470bus:FRS1022024-01-012024-12-3101649470bus:AuditExemptWithAccountantsReport2024-01-012024-12-3101649470bus:Director12024-01-012024-12-3101649470bus:Director22024-01-012024-12-3101649470bus:Director42024-01-012024-12-3101649470bus:CompanySecretary12024-01-012024-12-3101649470bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP